Title : Treatment of metastatic breast cancer with 𝑛𝑎𝑏-paclitaxel in the community practice setting: a US Oncology survey.

Pub. Date : 2015 May

PMID : 26029934






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 OBJECTIVE: To report on experience with nab-paclitaxel for human epidermal growth factor receptor 2 (HER2)-negative MBC and identify patient characteristics affecting nab-paclitaxel treatment patterns in the community practice setting. nab erb-b2 receptor tyrosine kinase 2 Homo sapiens
2 OBJECTIVE: To report on experience with nab-paclitaxel for human epidermal growth factor receptor 2 (HER2)-negative MBC and identify patient characteristics affecting nab-paclitaxel treatment patterns in the community practice setting. nab erb-b2 receptor tyrosine kinase 2 Homo sapiens
3 CONCLUSIONS: In the community setting, nab-paclitaxel 100 mg/m2 weekly was the most commonly used starting dose for patients with HER2-negative MBC, including those with aggressive disease characteristics. nab erb-b2 receptor tyrosine kinase 2 Homo sapiens